<html><body><h2>Case: 1192166</h2><h3> CDS Time: 1988-03-21</h3>
<patient name=1192166>
88.0 year old White_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">88</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">10</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">150</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">49</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Chloride</td><td width="200">102.0</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">34</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">60</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">B 12</td><td width="200">493.0</td><td width="200">1986-1-11</td></tr>
<tr><td width="200">Weight</td><td width="200">165</td><td width="200">1987-12-30</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">117</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">100</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">SGOT</td><td width="200">17</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">116</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Height</td><td width="200">61</td><td width="200">1986-7-25</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">100</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">BUN</td><td width="200">33</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">HCT</td><td width="200">37</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Sodium</td><td width="200">140</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.3</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">8</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Pulse</td><td width="200">82</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">PLT</td><td width="200">190</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">WBC</td><td width="200">9</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">eGFR</td><td width="200">41</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">SGPT</td><td width="200">33</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Hepatitis_B_Surface_Antigen</td><td width="200">Negative</td><td width="200">1985-7-1</td></tr>
<tr><td width="200">Hepatitis_C_Status</td><td width="200">Negative</td><td width="200">1985-7-1</td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Osteoporosis</td><td width="200"></td><td width="200">1987-4-3</td></tr>
<tr><td width="200">Obstructive_Pulmonary_Disease</td><td width="200"></td><td width="200">1987-3-22</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1987-3-24</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1988-3-21</td></tr>
<tr><td width="200">edema</td><td width="200"></td><td width="200">1988-1-13</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1987-12-1</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1987-3-22</td></tr>
</table>
<p><b>Medications:</b> triamterene(37.5) aspirin(325.0) simvastatin(20.0) lisinopril(40.0) nitrate(60.0) hydrochlorothiazide(0.0) glimepiride(8.0) furosemide(40.0) Insulin(1.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">CRI</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(1.3/1987-10-14) && Sex(Female) && Creatinine(1.3/1987-10-14)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(34.0/1987-3-21)]()</td></tr>
<tr><td width="200">Presence of K sparing diuretics</td>
<td width="200"></td>
<td width="200"> K sparing diuretics[presence of K sparing diuretics]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(88.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(41.0/1987-10-14)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(41.0/1987-10-14)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(88.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">MI no HF</td>
<td width="200"></td>
<td width="200"> MI no HF[Absence of HF && Presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]()</td></tr>
<tr><td width="200">Most recent K>=5</td>
<td width="200"></td>
<td width="200"> Most recent K>=5[Potassium(5.2/1987-10-14)]()</td></tr>
<tr><td width="200">Osteoporosis</td>
<td width="200">1987-04-03</td>
<td width="200"> Osteoporosis()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1987-03-22</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-03-24</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1987-12-01</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1988-03-21</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">Respiratory_Diseases</td>
<td width="200">1987-03-22</td>
<td width="200"> Obstructive_Pulmonary_Disease()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1985-07-01</td>
<td width="200"> Hepatitis_C_Status()
<tr> <td width="200"></td>
<td width="200">1985-07-01</td>
<td width="200"> Hepatitis_B_Surface_Antigen()
<tr> <td width="200"></td>
<td width="200">1988-01-13</td>
<td width="200"> edema()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
<p><b>Allergies and Adverse Reactions:</b> <ul>
<li>Substance: sulfonamides Reaction: 
<li>Substance: sulfonamides Reaction: 
 </ul>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage B HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(49.0/1987-3-21))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b>Secondary prevention</b><br>
<ul>
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Beta blocker stage B post MI(Carvedilol)<ul><li><font color=FF0000>Compelling indications:  MI no HF(MI no HF[Absence of HF && Presence of MI]) </font><li>preference: preferred</ul><li>ARB<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: preferred</ul><li>digoxin<ul><li>preference: neutral<li>No comment</ul><li>Beta Blocker Stage B no MI<ul><li>preference: neutral<li>No comment</ul><li>Ace_Inhibitor(Captopril, Lisinopril)<ul><li>Already being used<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: ruled out</ul><li>NDHP CCB<ul><li>Contraindications:  Myocardial_Infarction(Myocardial_Infarction) <li>preference: ruled out</ul></ul></body></html>